What Is Biotransformation? How the Body Processes Drugs

Biotransformation is the process by which living organisms chemically alter substances, whether those are drugs, food compounds, pollutants, or the body’s own hormones. In humans, the liver does the heaviest lifting, using families of enzymes to convert fat-soluble molecules into water-soluble ones that the kidneys or bile can flush out. But biotransformation is not limited to the liver, or even to humans. Gut bacteria, plants, soil microbes, and insects all run their own versions of this chemistry, and the consequences reach well beyond medicine into environmental cleanup, food production, and industrial manufacturing.

What Happens During Biotransformation

The process is traditionally divided into two broad stages. In the first, sometimes called Phase I, enzymes introduce or expose a small reactive chemical handle on the molecule. The most important group of enzymes here is the cytochrome P450 (CYP) family, a set of proteins embedded in cell membranes. In humans, CYP enzymes from just three gene families account for roughly 80 percent of oxidative drug metabolism and about half of the total elimination of commonly prescribed medications.¹ These enzymes mainly add oxygen atoms, strip away small chemical groups, or break rings open, making the molecule slightly more polar and setting it up for the next step.

In Phase II, a second set of enzymes attaches a bulky, water-loving tag to the molecule. Glucuronidation is one of the most common of these reactions. The enzymes responsible, called UGTs, work by first binding a sugar-acid cofactor and then coupling it to the drug or its Phase I product, producing a conjugate the body can excrete efficiently.² Other Phase II reactions include sulfation, acetylation, and attachment of the antioxidant molecule glutathione. The net effect of both phases is to make foreign chemicals less biologically active and easier to eliminate, though there are important exceptions where the opposite happens.

A sometimes-overlooked third phase involves transporter proteins that physically pump the finished metabolites out of cells and into the bile or blood for excretion. P-glycoprotein is one well-studied transporter that sits in the cell membrane and actively pushes a wide range of chemically different drugs out of the cell.³ This pump can lower drug concentrations inside cells to levels too low to have an effect, which is one reason certain cancers resist chemotherapy.⁴

First-Pass Metabolism and Why Your Pill Dose Differs from an IV Dose

When you swallow a medication, it does not travel directly into your bloodstream. It first passes through the gut wall and then through the liver before reaching the rest of the body. At each stop, enzymes can break down a portion of the drug. This so-called first-pass effect is a major reason oral doses are often much larger than doses given by injection. Both the liver and the intestine contain drug-metabolizing enzymes that can substantially reduce the amount of active drug that makes it into general circulation.⁵

How steep this first-pass loss can be varies enormously from one compound to another. In a study of the licorice-derived compound glabridin in rats, the hepatic first-pass effect alone accounted for about 62 percent of the dose, helping explain why only around 7 percent of the oral dose reached the bloodstream.⁶ Some well-known medications face similar challenges in humans, which is why drugs like nitroglycerin are given under the tongue or through skin patches rather than as pills.

When Biotransformation Makes Things Worse

The textbook story of biotransformation is reassuring: the body detoxifies a foreign chemical and flushes it out. But the same enzymatic machinery can sometimes convert an innocuous molecule into something more dangerous than what you started with. This process, called bioactivation, has been recognized since the 1970s as a major mechanism of drug- and chemical-induced toxicity.⁷

A classic example involves acetaminophen (paracetamol). At normal doses, the liver handles it mostly through Phase II conjugation. But a small fraction is converted by CYP enzymes into a highly reactive intermediate. When the liver’s supply of glutathione is overwhelmed, as happens in overdose, that reactive intermediate attacks liver proteins and causes potentially fatal damage. Glutathione-dependent biotransformation is itself a double-edged sword: while glutathione usually neutralizes dangerous intermediates, the conjugation pathway can actually generate toxic products from certain halogen-containing compounds, including some industrial solvents linked to kidney damage and cancer.⁸

Drug companies now routinely screen new candidates for bioactivation potential early in development. The concern centers on the “hapten hypothesis,” where a reactive intermediate binds to a protein, the immune system recognizes the modified protein as foreign, and the resulting immune response causes unpredictable toxicity in a small fraction of patients.⁹ These so-called idiosyncratic reactions are notoriously hard to predict because they depend on individual immune responses, not simple dose-toxicity curves. Novel bioactivation pathways continue to be discovered, including one involving a class of isoxazole-containing compounds that was only characterized in recent years.¹⁰

Genetic Variation and Why the Same Dose Affects People Differently

One of the most practically significant aspects of biotransformation is that it varies from person to person, largely because of inherited differences in enzyme genes. The CYP genes are highly variable across human populations, with dozens of known variants that alter how fast or slow the encoded enzyme works. These genetic differences sort people into categories that pharmacologists call poor, intermediate, extensive, and ultrarapid metabolizers, and the distribution of these categories depends strongly on ethnic background.¹¹

The practical consequences are real. A poor metabolizer given a standard dose of codeine, for instance, may get almost no pain relief because codeine needs CYP2D6 to be converted into its active form, morphine. An ultrarapid metabolizer given the same dose may convert it too quickly and experience dangerous levels of morphine. Population-scale genetic studies have mapped out the global landscape of these variants, confirming that both well-known and rarer mutations contribute meaningfully to functional variability across different CYP genes.¹² Pharmacogenomic testing, which reads a patient’s relevant CYP gene variants from a cheek swab or blood sample, is increasingly used to guide dosing for drugs like warfarin, certain antidepressants, and some cancer therapies.

Drug Interactions Through Shared Enzymes

Because many drugs pass through the same small set of CYP enzymes, two medications taken together can interfere with each other’s biotransformation. One drug may block (inhibit) a CYP enzyme, causing a second drug to accumulate to dangerously high levels. Another may ramp up (induce) enzyme production, causing a co-administered drug to be cleared so fast it never reaches an effective concentration.¹³ Grapefruit juice became the poster child for this phenomenon because compounds in it inhibit CYP3A4 in the intestinal wall, boosting the absorption of dozens of medications. St. John’s wort, on the other hand, is a potent inducer that can make birth control pills and immunosuppressants less effective.

These interactions are not limited to prescription drugs. Supplements, herbal products, and even dietary components can shift enzyme activity. This is one reason pharmacists and doctors ask about everything you take, not just prescription medications.

Your Gut Bacteria Run Their Own Biotransformation Lab

The trillions of bacteria living in the human gut harbor their own vast toolkit of enzymes. These microbes can directly metabolize drugs and other foreign chemicals in ways the human body cannot. Gut bacteria are especially good at reductive reactions, where they strip oxygen or add hydrogen to molecules, a capability that human cells are comparatively weak at. Beyond reduction, gut microbes perform acetylation, demethylation, dehalogenation, and the hydrolysis of conjugates that Phase II enzymes worked to create.¹⁴

That last capability, breaking apart conjugates, has real toxicological consequences. The liver may attach a glucuronide tag to a potentially harmful compound and dump it into the bile for excretion through the intestines. But gut bacteria equipped with an enzyme called beta-glucuronidase can snip that tag off, regenerating the active or toxic compound and allowing it to be reabsorbed. This recycling loop contributes to the gut toxicity of certain cancer drugs.

Microbiome-driven biotransformation is also essential for some drugs to work at all. The earliest sulfonamide antibiotics, prontosil and neoprontosil, are inactive until gut bacteria cleave their azo bonds to release the active component sulfanilamide.¹⁵ The human gut microbiome, home to an estimated 10 to 100 trillion microbial cells, effectively acts as a metabolic organ in its own right.¹⁶ Because the composition of this microbial community varies from person to person and shifts with diet, antibiotics, and illness, it adds yet another layer of individual variability to drug response.

Age Changes the Equation

Newborns and young infants metabolize drugs very differently from adults. Many drug-metabolizing enzymes are immature at birth, leading to slower clearance and longer-lasting drug effects.¹⁷ Studies measuring CYP enzyme levels directly in human liver tissue have shown that certain isoforms, like CYP1A2 and CYP2C19, are essentially absent in neonates. In contrast, CYP3A7, a fetal-specific form, is at its highest levels in this age group. Total CYP abundance peaks in children between one and two years of age and then gradually settles into the adult pattern.¹⁸

The pattern is similar for alcohol-metabolizing enzymes. The proteins that break down alcohol (alcohol dehydrogenases) are present at only a fraction of adult levels in newborns, with some forms more than a hundred times lower. These levels climb steeply during the first year of life and mostly reach adult values by early childhood.¹⁹ At the other end of life, aging brings declining liver mass, reduced blood flow, and sometimes lower enzyme activity, though the effect is more variable than in newborns and depends heavily on the specific enzyme.

Time of Day Matters Too

Biotransformation is not a steady-state process. The body’s internal clock regulates it in ways that can meaningfully alter how a drug is handled depending on when you take it. All three phases of drug metabolism, the initial enzymatic modification, the conjugation step, and the transporter-mediated excretion, are under circadian control.²⁰ The activity of different CYP isoforms, along with the enzymes handling glucuronidation, sulfation, and acetylation, all fluctuate over a 24-hour cycle. Even the liver’s concentration of glutathione, the body’s primary defense against reactive intermediates, follows a daily rhythm.²¹

These rhythms help explain chronopharmacokinetics, the observation that the same drug taken in the morning versus the evening can produce different blood levels and side-effect profiles. They also explain chronotoxicity: certain chemicals are more liver-damaging at one time of day than another, because the enzyme and glutathione defenses available to neutralize them are lower during particular hours. The field of chronopharmacology, while still young, is beginning to influence dosing strategies for drugs like statins and some chemotherapy agents.

Beyond the Body’s Own Molecules

The same CYP enzymes that process drugs also handle the body’s own hormones. Steroid hormones like cortisol, estrogen, and testosterone are inactivated through CYP-mediated hydroxylation and then tagged with glucuronide or sulfate groups for excretion, using the same Phase I and Phase II logic as drug metabolism.²² This overlap matters clinically. Some drugs can induce or inhibit the same enzymes that metabolize hormones, potentially shifting hormone levels. Certain anti-seizure medications, for example, speed up estrogen metabolism enough to reduce the effectiveness of hormonal contraceptives.

Species Differences and the Challenge of Animal Testing

Drug development still relies heavily on animal models to predict how a new compound will behave in people. But the biotransformation machinery differs substantially across species. While some enzymes, like CYP2E1, behave similarly enough that results translate reasonably well, others show pronounced differences. The CYP1A, 2C, 2D, and 3A subfamilies, which handle the bulk of human drug metabolism, all display significant inter-species variability in catalytic activity.²³ A drug that is safely cleared in a mouse may form a toxic intermediate in a human, or vice versa. This is one reason why seemingly promising drug candidates sometimes fail in human trials despite looking safe in animals, and why regulators increasingly push for human-relevant testing platforms.

New organ-on-a-chip technologies are trying to bridge this gap. Researchers have built miniature liver models on microfluidic chips using human stem-cell-derived tissue that expresses a broad panel of Phase I and Phase II enzymes along with key drug transporters.²⁴ These systems can metabolize drugs, evaluate toxicity, and even simulate first-pass metabolism by connecting a gut-like compartment to the liver chip in series.²⁵ They are not yet ready to replace animal studies entirely, but they represent a meaningful step toward more accurate, human-specific predictions of biotransformation.

Biotransformation in the Environment

Microorganisms have been transforming chemicals in the environment for billions of years, and researchers are increasingly looking to harness that capacity on purpose. One ambitious area is plastic pollution. A global survey of environmental DNA from ocean and soil samples identified over 30,000 enzyme candidates with the potential to degrade ten different plastic types, suggesting that microbial communities are already evolving in response to plastic pollution.²⁶ While most of these enzymes have not been individually validated, the sheer number hints at an untapped reservoir of biotransformation potential.

Microbes can also change the toxicity of pollutants already stuck to plastic. Marine anaerobic bacteria colonizing microplastic particles were shown to reductively dechlorinate PCBs (persistent industrial pollutants) sorbed onto the plastic surface. The dechlorination began within two weeks on microplastics, faster than the same process on contaminated sediment, potentially altering the toxicity profile of PCB-laden plastic debris in the ocean.²⁷

Plants have their own biotransformation capacity, and genetic engineering is pushing it further. Transgenic alfalfa plants engineered to co-express a human CYP enzyme (CYP2E1) alongside a glutathione-linking enzyme showed dramatically improved ability to tolerate and accumulate both mercury and trichloroethylene from contaminated soil, demonstrating a strategy for cleaning up sites polluted with mixed heavy-metal and organic contaminants.²⁸

Industrial Uses and the Flavor in Your Food

Pharmaceutical manufacturing has embraced biotransformation as a production method, not just a metabolic obstacle to work around. Enzymes carry out chemical reactions with a precision that traditional synthetic chemistry struggles to match, producing single mirror-image forms of molecules that would otherwise come as unusable mixtures of left- and right-handed versions. Hydrolases and oxidoreductases are the workhorses of industrial biocatalysis, used at scale to make chiral building blocks for drugs.²⁹

The food and fragrance industries benefit similarly. Microbial biotransformation has become a favored route for producing natural flavor and aroma compounds. Bacteria, yeasts, and molds possess diverse enzymatic machinery capable of converting cheap precursor molecules into high-value aromatic compounds with both high selectivity and a lighter environmental footprint than chemical synthesis.³⁰ Vanillin, for instance, can be produced by microbial conversion of ferulic acid found in agricultural waste, offering a “natural” label that chemical synthesis cannot.

An Evolutionary Arms Race Written in Enzymes

The diversity of biotransformation enzymes across species is not accidental. In insects, the size of the CYP gene family varies wildly, and much of that variation appears to reflect an evolutionary arms race with the plants they eat. Plants produce toxic defense chemicals; insects evolve new or duplicated CYP genes to detoxify them; plants, in turn, evolve new toxins. Studies comparing specialist and generalist moths have found a correlation between dynamic, rapidly evolving CYP gene clusters and the ability to metabolize host-plant defenses, consistent with an adaptive process driven by ecological interaction rather than random genetic drift.³¹

This perspective reframes biotransformation as something broader than drug metabolism. It is a fundamental survival strategy that has shaped genome architecture across the animal and plant kingdoms for hundreds of millions of years. The same enzyme families that let a caterpillar eat a toxic leaf are, in modified form, the ones deciding how quickly you clear a dose of ibuprofen.

Tracking Biotransformation Products You Did Not Know Existed

One of the frontiers in biotransformation research involves finding metabolites that nobody predicted. Traditional studies assume you know what the parent compound might turn into and then look for those specific products. But newer analytical approaches flip the process around. By feeding organisms a compound labeled with a stable heavy isotope alongside the normal version, researchers can scan for any metabolite that carries the isotope signature, revealing transformation products that would otherwise be invisible against the complex chemical background of a living system.³²

This strategy has uncovered surprises. When applied to wheat exposed to the fungal toxin deoxynivalenol, it revealed previously unknown conjugates the plant had created. Applied to the model plant Arabidopsis exposed to the drug gemfibrozil, it identified eleven novel Phase II conjugates, including amino acid and peptide conjugations that had not been anticipated.³³ These findings matter because unrecognized biotransformation products of contaminants in crops could end up in the food supply, carrying biological activity that food safety testing would miss if it were only looking for the parent compound.